Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Monno

Showing results (81-90 of 96) with videos related to

Pageof 10
Sort By:
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohortAntonio Di Biagio, Roberta Prinapori, Diana Giannarelli, et al.
Antiviral Research|October 21, 2019
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the differenceAndrea Giacomelli, Alessia Lai, Marco Franzetti, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2012
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapySilvia Baroncelli, Clementina Maria Galluzzo, Liliana Elena Weimer, et al.
AIDS Care|November 11, 2020
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort studyFilippo Lagi, Seble Tekle Kiros, Simona Di Giambenedetto, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 20, 2007
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis)Stefano Rusconi, Nicola Gianotti, Fulvio Adorni, et al.
Antiviral Therapy|March 3, 2020
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCADavide Fiore Bavaro, Domenico Di Carlo, Barbara Rossetti, et al.
AIDS (London, England)|October 17, 2018
The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapyAnna Schultze, Carlo Torti, Alessandro Cozzi-Lepri, et al.
Plos One|January 12, 2016
HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug UsersAlessia Lai, Giorgio Bozzi, Marco Franzetti, et al.
Journal of Medical Virology|October 29, 2010
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practiceMattia C F Prosperi, Maurizio Zazzi, Grazia Punzi, et al.
Current HIV Research|July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patientsAnnalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Pageof 10

Showing results (81-90 of 96) with videos related to

Sort By:
Pageof 10
The Journal of Antimicrobial Chemotherapy|August 24, 2012
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohortAntonio Di Biagio, Roberta Prinapori, Diana Giannarelli, et al.
Antiviral Research|October 21, 2019
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the differenceAndrea Giacomelli, Alessia Lai, Marco Franzetti, et al.
The Journal of Antimicrobial Chemotherapy|February 25, 2012
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapySilvia Baroncelli, Clementina Maria Galluzzo, Liliana Elena Weimer, et al.
AIDS Care|November 11, 2020
Long-term maintenance of virologic suppression in native and migrant HIV-1 naïve patients: an Italian cohort studyFilippo Lagi, Seble Tekle Kiros, Simona Di Giambenedetto, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 20, 2007
Determinants of HIV-1 genotypic resistance to darunavir (TMC114) in a large Italian resistance database (Antiretroviral Resistance Cohort Analysis)Stefano Rusconi, Nicola Gianotti, Fulvio Adorni, et al.
Antiviral Therapy|March 3, 2020
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCADavide Fiore Bavaro, Domenico Di Carlo, Barbara Rossetti, et al.
AIDS (London, England)|October 17, 2018
The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapyAnna Schultze, Carlo Torti, Alessandro Cozzi-Lepri, et al.
Plos One|January 12, 2016
HIV-1 A1 Subtype Epidemic in Italy Originated from Africa and Eastern Europe and Shows a High Frequency of Transmission Chains Involving Intravenous Drug UsersAlessia Lai, Giorgio Bozzi, Marco Franzetti, et al.
Journal of Medical Virology|October 29, 2010
Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practiceMattia C F Prosperi, Maurizio Zazzi, Grazia Punzi, et al.
Current HIV Research|July 16, 2009
Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patientsAnnalisa Saracino, Laura Monno, Alessandra Tartaglia, et al.
Pageof 10